Brian Zambrowicz

14.0k total citations · 1 hit paper
82 papers, 6.8k citations indexed

About

Brian Zambrowicz is a scholar working on Molecular Biology, Endocrinology, Diabetes and Metabolism and Surgery. According to data from OpenAlex, Brian Zambrowicz has authored 82 papers receiving a total of 6.8k indexed citations (citations by other indexed papers that have themselves been cited), including 42 papers in Molecular Biology, 32 papers in Endocrinology, Diabetes and Metabolism and 21 papers in Surgery. Recurrent topics in Brian Zambrowicz's work include Diabetes Treatment and Management (18 papers), Pancreatic function and diabetes (16 papers) and CRISPR and Genetic Engineering (11 papers). Brian Zambrowicz is often cited by papers focused on Diabetes Treatment and Management (18 papers), Pancreatic function and diabetes (16 papers) and CRISPR and Genetic Engineering (11 papers). Brian Zambrowicz collaborates with scholars based in United States, Germany and Czechia. Brian Zambrowicz's co-authors include Arthur Sands, Philippe Soriano, Leonard A. Herzenberg, Steve Fiering, William G. Kerr, Akira Imamoto, Richard D. Palmiter, Glenn A. Friedrich, Pablo Lapuerta and Gwenn M. Hansen and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Brian Zambrowicz

80 papers receiving 6.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Disruption of overlapping transcripts in the ROSA βgeo 26 gene trap strain leads to widespread expression of β-galactosidase in mouse embryos and hematopoietic cells

1997 729 citations Brian Zambrowicz et al. Proceedings of the National Academy of Sciences profile →

Peers

Brian Zambrowicz

EDM

SURGE

GENET

ONCOL

Ikuo Inoue Japan

Minho Shong South Korea

Arthur Sands United States

Herbert Y. Gaisano Canada

Emmanuel Van Obberghen France

Xiao‐Jian Sun United States

Andrew Plump United States

Chieko Mineo United States

Liam J. Murphy Canada

Yoshio Fujitani Japan

Ikuo Inoue Japan

Brian Zambrowicz

2.5k ×0.7

1.2k ×0.7

EDM

1.2k ×0.9

SURGE

661 ×0.6

GENET

341 ×0.4

ONCOL

Citations per year, relative to Brian Zambrowicz Brian Zambrowicz (= 1×) peers Ikuo Inoue

Countries citing papers authored by Brian Zambrowicz

Since Specialization

Citations

This map shows the geographic impact of Brian Zambrowicz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brian Zambrowicz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brian Zambrowicz more than expected).

Fields of papers citing papers by Brian Zambrowicz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brian Zambrowicz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brian Zambrowicz. The network helps show where Brian Zambrowicz may publish in the future.

Co-authorship network of co-authors of Brian Zambrowicz

This figure shows the co-authorship network connecting the top 25 collaborators of Brian Zambrowicz. A scholar is included among the top collaborators of Brian Zambrowicz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brian Zambrowicz. Brian Zambrowicz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chim, Shek Man, Kristen E. Howell, Alexandros G. Kokkosis, et al.. (2024). A Human Brain-Chip for Modeling Brain Pathologies and Screening Blood–Brain Barrier Crossing Therapeutic Strategies. Pharmaceutics. 16(10). 1314–1314. 2 indexed citations

Kerk, Sze Yen, Yu Bai, Charleen Hunt, et al.. (2022). Homozygous ALS-linked FUS P525L mutations cell- autonomously perturb transcriptome profile and chemoreceptor signaling in human iPSC microglia. Stem Cell Reports. 17(3). 678–692. 18 indexed citations

Lee, Jeffrey, Jingjing Wang, Lawrence Miloscio, et al.. (2022). Production of large, defined genome modifications in rats by targeting rat embryonic stem cells. Stem Cell Reports. 18(1). 394–409. 1 indexed citations

Powell, D.R., Jean‐Pierre Revelli, Deon Doree, et al.. (2021). High-Throughput Screening of Mouse Gene Knockouts Identifies Established and Novel High Body Fat Phenotypes. Diabetes Metabolic Syndrome and Obesity. Volume 14. 3753–3785. 9 indexed citations

Young, Tara M., Claudia Reyes, Elizabeth Pasnikowski, et al.. (2020). Autophagy protects tumors from T cell–mediated cytotoxicity via inhibition of TNFα-induced apoptosis. Science Immunology. 5(54). 79 indexed citations

Kleiner, Sandra, Daniel R. Gomez, Erqian Na, et al.. (2018). Mice harboring the human SLC30A8 R138X loss-of-function mutation have increased insulin secretory capacity. Proceedings of the National Academy of Sciences. 115(32). E7642–E7649. 40 indexed citations

Kulke, Matthew H., Dieter Hoersch, Martyn Caplin, et al.. (2016). Telotristat etiprate shows benefit in treating patients With carcinoid syndrome that is inadequately controlled by somatostatin analog therapy in the phase 3 TELESTAR clinical trial. Pancreas. 45(3). 478–478. 1 indexed citations

Powell, David R., Christopher M. DaCosta, Melinda Smith, et al.. (2014). Effect of LX4211 on Glucose Homeostasis and Body Composition in Preclinical Models. Journal of Pharmacology and Experimental Therapeutics. 350(2). 232–242. 44 indexed citations

Zambrowicz, Brian, Pablo Lapuerta, Paul Strumph, et al.. (2014). LX4211 Therapy Reduces Postprandial Glucose Levels in Patients With Type 2 Diabetes Mellitus and Renal Impairment Despite Low Urinary Glucose Excretion. Clinical Therapeutics. 37(1). 71–82.e12. 34 indexed citations

10.

Lapuerta, Pablo, Julio Rosenstock, Brian Zambrowicz, et al.. (2013). Study Design and Rationale of a Dose‐Ranging Trial of LX4211, a Dual Inhibitor of SGLT1 and SGLT2, in Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy. Clinical Cardiology. 36(7). 367–371. 12 indexed citations

11.

Powell, David R., Melinda Smith, Jennifer Greer, et al.. (2013). LX4211 Increases Serum Glucagon-Like Peptide 1 and Peptide YY Levels by Reducing Sodium/Glucose Cotransporter 1 (SGLT1)–Mediated Absorption of Intestinal Glucose. Journal of Pharmacology and Experimental Therapeutics. 345(2). 250–259. 156 indexed citations

12.

Zambrowicz, Brian, Zhi‐Ming Ding, Ike Ogbaa, et al.. (2013). Effects of LX4211, a Dual SGLT1/SGLT2 Inhibitor, Plus Sitagliptin on Postprandial Active GLP-1 and Glycemic Control in Type 2 Diabetes. Clinical Therapeutics. 35(3). 273–285.e7. 65 indexed citations

13.

Zambrowicz, Brian, J Freiman, Phil Brown, et al.. (2012). LX4211, a Dual SGLT1/SGLT2 Inhibitor, Improved Glycemic Control in Patients With Type 2 Diabetes in a Randomized, Placebo-Controlled Trial. Clinical Pharmacology & Therapeutics. 92(2). 158–169. 202 indexed citations

14.

Sonnenburg, William K., Daiguan Yu, Wei Xiong, et al.. (2009). GPIHBP1 stabilizes lipoprotein lipase and prevents its inhibition by angiopoietin-like 3 and angiopoietin-like 4. Journal of Lipid Research. 50(12). 2421–2429. 105 indexed citations

15.

Desai, Urvi, Kyu Hyuck Chung, Cuihua Gao, et al.. (2007). Lipid-lowering effects of anti-angiopoietin-like 4 antibody recapitulate the lipid phenotype found in angiopoietin-like 4 knockout mice. Proceedings of the National Academy of Sciences. 104(28). 11766–11771. 155 indexed citations

16.

Wlodarczyk, Bogdan J., et al.. (2007). Mouse Fkbp8 activity is required to inhibit cell death and establish dorso-ventral patterning in the posterior neural tube. Human Molecular Genetics. 17(4). 587–601. 41 indexed citations

17.

Abuin, Alejandro, Gwenn M. Hansen, & Brian Zambrowicz. (2007). Gene Trap Mutagenesis. Handbook of experimental pharmacology. 129–147. 31 indexed citations

18.

Abuin, Alejandro, Kathleen H. Holt, Kenneth A. Platt, Arthur Sands, & Brian Zambrowicz. (2002). Full-speed mammalian genetics: in vivo target validation in the drug discovery process. Trends in biotechnology. 20(1). 36–42. 32 indexed citations

19.

Guidi, Cynthia J., Arthur Sands, Brian Zambrowicz, et al.. (2001). Disruption of Ini1 Leads to Peri-Implantation Lethality and Tumorigenesis in Mice. Molecular and Cellular Biology. 21(10). 3598–3603. 241 indexed citations

20.

Zambrowicz, Brian & Glenn A. Friedrich. (1998). Comprehensive mammalian genetics: history and future prospects of gene trapping in the mouse. The International Journal of Developmental Biology. 42(7). 1025–1036. 36 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact